Palisade Bio (PALI) Gains from Investment Securities (2013 - 2023)
Palisade Bio (PALI) posted quarterly Gains from Investment Securities of -$8000.0 for Q4 2023, down 102.39% quarter-over-quarter from $334133.0 in Q1 2014.
Powered by 
Analysis
Palisade Bio (PALI) Gains from Investment Securities (2013 - 2023) Analysis & Trends
Palisade Bio (PALI) has reported Gains from Investment Securities for 3 consecutive years, with -$8000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Gains from Investment Securities changed N/A year-over-year to -$8000.0; the TTM figure through Dec 2023 stood at -$8000.0 (changed N/A YoY), while the FY2023 annual figure was $204000.0, changed N/A from the prior year.
- Gains from Investment Securities eased to -$8000.0 in Q4 2023 per PALI's latest filing, from $334133.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at -$8000.0 in Q4 2023 and bottomed at -$8000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -8,000.00 |
| Mar 31, 2014 | 334,133.00 |
| Dec 31, 2013 | 105,647.00 |
| Sep 30, 2013 | 677,883.00 |
| Jun 30, 2013 | 188,317.00 |
| Mar 31, 2013 | -6,518.00 |